Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Daigo Michimata, MD, Kazunori Murai, MD PhD, Yasuro Miyairi, MD, PhD, Yoshiaki Okano, MD, PhD, Yuuzou Suzuki, MD, PhD, Hiroyuki Hamada, MD, Akiyoshi Sato, MD, PhD, Tatsuo Oyake, Shugo Kowata, MD, PhD, Yasuhiko Tsukushi, MD, PhD, Norifumi Sugawara, MD, PhD, Akihiro Otsu, MD, PhD, Kenji Shimosegawa, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2019) 134 (Supplement_1): 2928.

https://doi.org/10.1182/blood-2019-125066

Published: 2019

Journal Articles

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

Tatsuo Oyake, Norifumi Sugawara, MD, PhD, Shinri Miyajima, MD, Kazuki Kiyohara, MD, Maki Nishiya, MD PhD, Tadashi Shimoyama, MD PhD, Yuka Takemasa-Fujisawa, MD PhD, Ryosei Sasaki, MD PhD, Wataru Izumita, MD, Yasuhiko Tsukushi, MD, PhD, Akihiro Otsu, MD, PhD, Takahiro Mine, MD, Takeshi Sugawara, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, PhD, Ichiro Hanamura, MD PhD, Shugo Kowata, MD, PhD, Shigeki Ito, MD, PhD

Blood (2019) 134 (Supplement_1): 4865.

https://doi.org/10.1182/blood-2019-131305

Published: 2019

Journal Articles

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Ryousei Sasaki, MD, PhD, Wataru Izumita, MD, Takahiro Mine, MD, Maki Asahi, MD, PhD, Yuzo Suzuki, MD, PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yasuhiko Tsukushi, MD, PhD, Yusei Aoki, MD, Shugo Kowata, MD, PhD, Ichiro Hanamura, MD, PhD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2016) 128 (22): 1607.

https://doi.org/10.1182/blood.V128.22.1607.1607

Published: 2016

Journal Articles

First-Line Dasatinib Treatment of CML-CP Leads to Earlier Achievement of MMR and MR4.5 with High Safety

Blood (2016) 128 (22): 3102.

https://doi.org/10.1182/blood.V128.22.3102.3102

Published: 2016

Journal Articles

Platelet Progenitors after Leaving Bone Marrow

Shugo Kowata, MD PhD, Ryo Togawa, MD, Yoshiaki Okano, MD, Sumio Isogai, PhD, Jiro Hitomi, MDPhD, Kazunori Murai, MDPhD, Shigeki Ito, MD PhD, Yoji Ishida, MD, PhD

Blood (2015) 126 (23): 2249.

https://doi.org/10.1182/blood.V126.23.2249.2249

Published: 2015

Journal Articles

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Tatsuo Oyake, MD PhD, Takayuki Masuda, MD PhD, Norifumi Sugawara, MD PhD, Maki Asahi, MD, Yuzo Suzuki, MD PhD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD PhD, Shigeki Ito, MD PhD, Yoji Ishida, MDPhD

Blood (2015) 126 (23): 4621.

https://doi.org/10.1182/blood.V126.23.4621.4621

Published: 2015

Journal Articles

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Tatsuo Oyake, MD, PhD, Yuka Fujisawa, MD, PhD, Norifumi Sugawara, MD, PhD, Yasunori Nakagawa, MD, PhD, Takahiro Mine, MD, Ichiro Hanamura, MD, PhD, Maki Asahi, MD, Yukiteru Fujishima, MD, Yusei Aoki, MD, Shugo Kowata, MD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 4954.

https://doi.org/10.1182/blood.V124.21.4954.4954

Published: 2014

Journal Articles

Index to Predict MMR at 12 Months in Chronic Phase Chronic Myeloid Leukemia Patients Based on the Area Under the Lymphocyte Curve

Kazunori Murai, PhD MD, Shigeki Ito, MD PhD, Shugo Kowata, MD, Tatsuo Oyake, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 4560.

https://doi.org/10.1182/blood.V124.21.4560.4560

Published: 2014

Journal Articles

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Tadashi Shimoyama, MD, Yoshiaki Okano, MD, Yukiteru Fujishima, MD, Tatsuo Oyake, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2014) 124 (21): 1456.

https://doi.org/10.1182/blood.V124.21.1456.1456

Published: 2014

Journal Articles

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Yukiteru Fujishima, MD, Yasuhiko Tsukushi, M.D., Takahiro Mine, MD., Tatsuo Oyake, M.D., Ph.D., Shigeki Ito, M.D., Ph.D., Yoji Ishida, M.D., Ph.D.

Blood (2013) 122 (21): 1071.

https://doi.org/10.1182/blood.V122.21.1071.1071

Published: 2013

Journal Articles

Novel Concept of Platelet Production From Megakaryocyte in Intact Bone Marrow: Proplatelet and Thick Protrusion.

Shugo Kowata, MD., Sumio Isogai, PhD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Koujiro Tohyama, PhD, Jiro Hitomi, MD, PhD, Yoji Ishida, MD, PhD

Blood (2012) 120 (21): 2300.

https://doi.org/10.1182/blood.V120.21.2300.2300

Published: 2012

Journal Articles

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Kazunori Murai, MD, PhD, Shugo Kowata, MD., Tatsuo Oyake, M.D., Ph.D., Tadashi Shimoyama, Maki Asahi, Sugawara Norifumi, Ryosei Sasaki, Suzuki Yuzo, Fujishima Yukiteru, Yasuhiko Tsukushi, M.D., Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2012) 120 (21): 2186.

https://doi.org/10.1182/blood.V120.21.2186.2186

Published: 2012

Journal Articles

Hepatotoxicity During Eltrombopag Administration Might Be Due to Necrosis of Hepatocytes

Kazunori Murai, MD, PhD, Shugo Kowata, MD, Akiko Abo, MD, PhD, Tatsuo Oyake, M.D., Ph.D., Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2011) 118 (21): 2228.

https://doi.org/10.1182/blood.V118.21.2228.2228

Published: 2011

Journal Articles

Bortezomib Induced Thrombocytopenia Might Be Due to the Inhibition of Proplatelet Formation of Megakaryocyte.

Kazunori Murai, MD, PhD, Shugo Kowata, MD, Akiko Abo, MD, PhD, Tatsuo Oyake, MD, PhD, Kenichi Nomura, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 3696.

https://doi.org/10.1182/blood.V116.21.3696.3696

Published: 2010

Journal Articles

Forming Cytoplasmic Fragment Is Implicated In the Final Step of Platelet Production

Shugo Kowata, MD, Kazunori Murai, MD, PhD, Kenichi Nomura, MD, PhD, Tatsuo Oyake, MD, PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 4793.

https://doi.org/10.1182/blood.V116.21.4793.4793

Published: 2010

Journal Articles

Micafungin Versus Voriconazole for Empirical Antifungal Therapy In Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized, Controlled Trial.

Tatsuo Oyake, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, PhD, Shigeki Ito, MD, PhD, Tomoaki Akagi, MD, PhD, Koumei Kubo, MD, PhD, Kenichi Sawada, MD, PhD, Yoji Ishida, MD, PhD

Blood (2010) 116 (21): 1062.

https://doi.org/10.1182/blood.V116.21.1062.1062

Published: 2010

Journal Articles

Deguelin Induces Cell Growth Arrest and Cell Death Via the Suppression of BCR-ABL and Survivin Expression in BCR-ABL-T315I Mutant Cells.

Tatsuo Oyake, MD, PhD, Shigeki Ito, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, Yoji Ishida, MD, PhD

Blood (2009) 114 (22): 4255.

https://doi.org/10.1182/blood.V114.22.4255.4255

Published: 2009

Journal Articles

The Role of Actin Nucleating Factors, Arp3 and mDia1, During Proplatelet Formation of Megakaryocytes.

Shugo Kowata, MD, Tatsuo Oyake, Shigeki Ito, MD, PhD, Kazunori Murai, MD, Yoji Ishida, MD, PhD

Blood (2009) 114 (22): 1472.

https://doi.org/10.1182/blood.V114.22.1472.1472

Published: 2009

Journal Articles

Recombinant Human Erythropoietin Administration Decreases the Frequency of Excessive Apoptosis in Erythroid Progenitors in the Model Mouse of Anemia Due to Chronic Renal Failure.

Tatsuo Oyake, MD, PhD, Shigeki Ito, MD, PhD, Shugo Kowata, MD, Kazunori Murai, MD, Yoji Ishida, MD, PhD

Blood (2007) 110 (11): 3668.

https://doi.org/10.1182/blood.V110.11.3668.3668

Published: 2007

Journal Articles

Mannose Labeled Liposome Containing DXR Administration Is Effective in Reversing Thrombocytopenia in the Model Mouse of Immune Thrombocytopenia.

Yoji Ishida, MD, Kazunori Murai, MD, Tatsuo Oyake, MD, Shugo Kowata, MD, Shigeki Ito, MD, Ryo Suzuki, PhD, Kazuo Maruyama, PhD

Blood (2007) 110 (11): 2109.

https://doi.org/10.1182/blood.V110.11.2109.2109

Published: 2007

NARROW

The Relationship between Molecular Response of BCR-ABL1 Transcripts within 6 Months and Deep Molecular Response at 18 Months to Dasatinib Treatment for Newly Diagnosed Patients with CML-CP

Doripenem Versus Meropenem As the First-Line Mono-Therapy in High-Risk Febrile Neutropenic Patients with Acute Leukemia: A Randomized, Controlled Trial

Comparison of Micafungin and Liposomal Amphotericin B for Empirical Antifungal Therapy in Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized Controlled Trial

First-Line Dasatinib Treatment of CML-CP Leads to Earlier Achievement of MMR and MR4.5 with High Safety

Platelet Progenitors after Leaving Bone Marrow

Presepsin (soluble CD14 subtype) Is Available in Febrile Neutropenic Patients with Hematological Malignancy As Diagnosis and Assesment Biomarker of Infections

Doripenem Versus Meropenem As the First-Line Empirical Therapy in High-Risk Febrile Neutropenic Patients with Hematological Malignancy: A Randomized, Controlled Trial

Index to Predict MMR at 12 Months in Chronic Phase Chronic Myeloid Leukemia Patients Based on the Area Under the Lymphocyte Curve

Dasatinib Is Effective in the Treatment of Mice Models with Immune Thrombocytopenia

Dasatinib Induced Thrombocytopenia Might Be Due To The Inhibition Of Proplatelet Formation Of Megakaryocytes Via The Pathways Including Rho/Rock and Rac

Novel Concept of Platelet Production From Megakaryocyte in Intact Bone Marrow: Proplatelet and Thick Protrusion.

Ponatinib Induced Thrombocytopenia Might Inhibit Proplatelet Formation of Megakaryocytes Via the Pathways Including Rho/Rock and Rac.

Hepatotoxicity During Eltrombopag Administration Might Be Due to Necrosis of Hepatocytes

Bortezomib Induced Thrombocytopenia Might Be Due to the Inhibition of Proplatelet Formation of Megakaryocyte.

Forming Cytoplasmic Fragment Is Implicated In the Final Step of Platelet Production

Micafungin Versus Voriconazole for Empirical Antifungal Therapy In Febrile Neutropenic Patients with Acute Myeloid Leukemia: A Randomized, Controlled Trial.

Deguelin Induces Cell Growth Arrest and Cell Death Via the Suppression of BCR-ABL and Survivin Expression in BCR-ABL-T315I Mutant Cells.

The Role of Actin Nucleating Factors, Arp3 and mDia1, During Proplatelet Formation of Megakaryocytes.

Recombinant Human Erythropoietin Administration Decreases the Frequency of Excessive Apoptosis in Erythroid Progenitors in the Model Mouse of Anemia Due to Chronic Renal Failure.

Mannose Labeled Liposome Containing DXR Administration Is Effective in Reversing Thrombocytopenia in the Model Mouse of Immune Thrombocytopenia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only